panel-7-defending-market-exclusivity-through-hatch
20 May 2026VideosAmericasHa Kung Wong, Venable | Sarah Fendrick, Alnylam Pharmaceuticals | Abby Markeson, Arcutis Biotherapeutics | Eberle Schultz, Sumitomo Pharma America

WATCH: Defending market exclusivity through Hatch-Waxman and BPCIA litigation strategies

The influx of biosimilars and generics requires innovator companies and challengers alike to continually refine their litigation tactics. This panel dissects current trends in Hatch-Waxman and BPCIA frameworks, providing a roadmap for defending franchises and navigating market entry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
6 November 2026   Uncertainty over whether a patent can be challenged through inter partes review at the USPTO has only increased since the discretionary denial policy was introduced, so how should companies plan? Mauricio Uribe and Maria Anderson of Davis Wright Tremaine explain.
Americas
17 June 2026   A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
Americas
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.